Live Feeds
● LIVE Updated 1h ago · 20 sources tracked

Moderna Shares More Than Double on Success of mRNA Cancer Vaccine

Moderna shares more than doubled following the announcement of positive Phase III trial results for intismeran, an mRNA-based individualized neoantigen therapy developed with Merck. The trial involved more than 1,000 patients and demonstrated that the vaccine helped prevent the return and spread of melanoma. The news also triggered stock surges for several sequencing companies. This development marks the first-ever positive Phase III results for an mRNA cancer vaccine, potentially opening the door for a wider range of oncology treatments.

RSS Source map (20)

What changed

The vaccine is now identified as intismeran and the trial included more than 1,000 patients.

Live updates

  1. Moderna and Merck Report Positive Phase III Results for Melanoma Vaccine

    Moderna shares more than doubled following the announcement of positive Phase III trial results for intismeran, an mRNA-based individualized neoantigen therapy developed with Merck. The trial involved more than 1,000 patients and demonstrated that the vaccine helped prevent the return and spread of melanoma. The news also triggered stock surges for several sequencing companies. This development marks the first-ever positive Phase III results for an mRNA cancer vaccine, potentially opening the door for a wider range of oncology treatments.

    Why it matters

    Melanoma is the deadliest form of skin cancer. The vaccine uses personalized mRNA technology to target specific neoantigens in a patient's tumor. This approach differs from traditional treatments by tailoring the therapy to the individual's cancer profile.

    What is confirmed

    • Moderna shares more than doubled following the success of an mRNA cancer vaccine.
    • The vaccine, known as intismeran, is designed to treat melanoma.
    • Moderna and Merck reported the first-ever positive Phase III results for an mRNA-based cancer vaccine.

    Still unconfirmed

    • The vaccine helped prevent the return and spread of melanoma in a trial of more than 1,000 patients.
    • Shares of several sequencing companies surged following the announcement.

    What to watch next

    • Regulatory approval filings for intismeran
    • Expansion of mRNA vaccine trials to other cancer types
    Sources used for this update (4)
    1. www.livemint.com — It now seems possible to vaccinate against cancer
    2. omaha.com — Moderna, Merck breakthrough could usher in cancer vaccines
    3. www.genengnews.com — StockWatch: Merck/Moderna Cancer Vaccine Gives a Shot in the Arm to Sequencing Companies, Too
    4. www.theglobeandmail.com — Why Tempus AI Skyrocketed This Week
    confidence 90%

  2. Moderna Shares Soar on mRNA Cancer Vaccine Success

    Moderna's shares surged after its personalized mRNA cancer vaccine, developed with Merck, showed promise in a late-stage Phase III trial for melanoma. The vaccine aims to treat the deadliest form of skin cancer and could lead to broader mRNA-based oncology treatments. Both companies are preparing for a potential market debut of the therapy.

    Why it matters

    The success of the mRNA cancer vaccine could revolutionize cancer treatment and expand the use of mRNA technology in oncology. Moderna's stock has more than doubled, causing an estimated $5 billion loss for short sellers. The vaccine's potential market debut could significantly impact the pharmaceutical and biotech industries.

    What is confirmed

    • Moderna's shares rose sharply after a personalized mRNA cancer vaccine developed with Merck showed promise in a late-stage Phase III trial targeting melanoma.
    • The experimental mRNA vaccine successfully cleared phase 3 clinical trials, the last step necessary before it can be approved by the FDA.
    • If ongoing studies in other cancers produce similar results, the technology could influence far more than cancer care itself.

    Still unconfirmed

    • The vaccine could change America in 7 surprising ways.

    What to watch next

    • FDA approval of the mRNA cancer vaccine
    • Market debut of the therapy
    • Results of ongoing studies in other cancers
    Sources used for this update (7)
    1. www.aol.com — Moderna's Comeback Is Finally Taking Shape -- and There May Be More Upside Ahead
    2. en.sedaily.com — SK hynix to Buy Back, Cancel 40 Trillion Won in Shares; KOSPI Retakes 6,800
    3. en.sedaily.com — Korea to Build 2 More Chip Fabs in Honam, Adding to 6-Plus Plan by 2040
    4. www.cheddar.com — Big Business This Week: Bond Market Turmoil and The Broader Economy
    5. www.nationalgeographic.com — Why Scientists Say This Personalized Cancer Vaccine Could Be a Game-Changer
    6. www.newsweek.com — Moderna’s Cancer Vaccine Could Change America in 7 Surprising Ways
    7. www.edaily.co.kr — Samyang Biopharm Hits Limit-Up as Moderna-MSD Cancer Vaccine Data Spark mRNA Rally [K-Bio Pulse]
    confidence 85%

  3. Moderna Shares Surge Following Positive mRNA Cancer Vaccine Trial Results

    Moderna shares rose sharply after a personalized mRNA cancer vaccine developed with Merck showed promise in a late-stage Phase III trial targeting melanoma. Market reactions varied by source, with reports of stock increases ranging from 90% to 177%, causing an estimated $5 billion loss for short sellers. The vaccine aims to treat the deadliest form of skin cancer and could lead to a broader wave of mRNA-based oncology treatments. Both companies are now preparing for a potential market debut of the therapy.

    Why it matters

    This development marks a shift for Moderna from COVID-19 vaccines toward personalized cancer treatment. The partnership with Merck (MSD) focuses on using mRNA technology to trigger specific immune responses against tumors. Success in melanoma trials serves as a proof of concept for applying similar technology to other cancer types.

    What is confirmed

    • Moderna and Merck developed an mRNA cancer vaccine that showed promise in a late-stage trial.
    • The vaccine is designed to treat melanoma.
    • Moderna stock experienced a significant price increase following the trial results.
    • The vaccine uses personalized mRNA technology.

    Still unconfirmed

    • Moderna shares doubled.

    What to watch next

    • Regulatory filing and approval dates for the melanoma vaccine
    • Expansion of Phase III trials to other cancer types
    • Official revenue projections for the vaccine market debut
    Sources used for this update (10)
    1. CNBC — Moderna, Merck cancer vaccine shows promise in late-stage trial; Moderna stock soars 90%
    2. WSJ — Moderna Shares Double on Success of mRNA Cancer Vaccine
    3. Bloomberg.com — Moderna’s 160% Surge Burns Shorts in ‘Painful’ $5 Billion Loss
    4. Clinical Trials Arena — MSD and Moderna eye cancer vaccine market debut on Phase III melanoma score
    5. KOMO — 'Another weapon' against cancer: Personalized mRNA vaccine shows promising results
    6. Reuters — Moderna, Merck breakthrough could usher in wave of cancer vaccines
    7. CBS News — Doctors explain how Moderna's melanoma mRNA vaccine could fight deadliest form of skin cancer
    8. Yahoo Finance — Why Did MRNA, MRK, TGT Stocks Jump To 52-Week Highs Today?
    9. The New York Times — From Covid to Cancer: How Moderna’s Stock Jumped 177% in a Day
    10. STAT — One of the most consequential year for cancer treatment, ever
    confidence 90%